Combined Therapy with Intravenous Immunoglobulins, Letermovir and (Val-)Ganciclovir in Complicated Courses of CMV-Infection in Transplant Recipients

The treatment options for cytomegalovirus (CMV) infections in immunosuppressed patients are limited, mainly consisting of (val-)ganciclovir (VGC/GCV) as the first-line treatment. We report on three transplant recipients, one stem cell transplant (allo-HSCT) patient and two kidney transplant (KTx) re...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Cristanziano, Veronica, Affeldt, Patrick, Trappe, Moritz, Wirtz, Maike, Heger, Eva, Knops, Elena, Kaiser, Rolf, Stippel, Dirk, Müller, Roman-Ulrich, Holtick, Udo, Scheid, Christoph, Kann, Martin, Kurschat, Christine E., Grundmann, Franziska
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8398864/
https://www.ncbi.nlm.nih.gov/pubmed/34442744
http://dx.doi.org/10.3390/microorganisms9081666
Descripción
Sumario:The treatment options for cytomegalovirus (CMV) infections in immunosuppressed patients are limited, mainly consisting of (val-)ganciclovir (VGC/GCV) as the first-line treatment. We report on three transplant recipients, one stem cell transplant (allo-HSCT) patient and two kidney transplant (KTx) recipients, with prolonged CMV viremia treated with a combined therapy based on letermovir (LMV), CMV-specific intravenous immunoglobulins (IVIg), and VGC/GCV, which led to the sustained control of CMV viremia in all patients.

Ejemplares similares